Literature DB >> 20194327

Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva.

Frederick S Kaplan1, Michael A Zasloff, Joseph A Kitterman, Eileen M Shore, Charles C Hong, David M Rocke.   

Abstract

BACKGROUND: Fibrodysplasia ossificans progressiva, a rare genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification in humans. However, little is known about the lifespan or causes of mortality in these patients. We undertook this study to determine the lifespan and causes of mortality in individuals who had fibrodysplasia ossificans progressiva.
METHODS: We reviewed comprehensive mortality reports from two large registries of patients with fibrodysplasia ossificans progressiva. Together, these registries comprise >90% of all known patients with this condition in the world. We noted the sex, dates of birth and death, and the cause of death for each individual. We verified the cause of death with extensive medical records, when available. We also collected date of birth, current age, and sex information for each living patient member of the International Fibrodysplasia Ossificans Progressiva Association.
RESULTS: Sixty deaths (thirty male and thirty female patients) were reported in the fibrodysplasia ossificans progressiva community during a thirty-three-year-period. For all sixty patients, the median age at the time of death was forty years (range, three to seventy-seven years). Data were sufficient to establish the cause of death in forty-eight (80%) of the sixty individuals. The median age at the time of death for the forty-eight patients (twenty-four male and twenty-four female patients) with an established cause of death was also forty years. The median lifespan estimated from the 371 individuals in the international fibrodysplasia ossificans progressiva community who were alive and the sixty who had died was fifty-six years (95% confidence interval, fifty-one to sixty years). The most common causes of death in patients with fibrodysplasia ossificans progressiva were cardiorespiratory failure from thoracic insufficiency syndrome (54%; median age, forty-two years) and pneumonia (15%; median age, forty years).
CONCLUSIONS: Fibrodysplasia ossificans progressiva is not only an extremely disabling disease but also a condition of considerably shortened lifespan. The most common cause of death in patients with fibrodysplasia ossificans progressiva is cardiorespiratory failure from thoracic insufficiency syndrome.

Entities:  

Mesh:

Year:  2010        PMID: 20194327      PMCID: PMC2827822          DOI: 10.2106/JBJS.I.00705

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  36 in total

1.  Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP).

Authors:  Jennifer L Fiori; Paul C Billings; Lourdes Serrano de la Peña; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

Review 2.  Thoracic insufficiency syndrome and exotic scoliosis.

Authors:  Robert M Campbell; Melvin D Smith
Journal:  J Bone Joint Surg Am       Date:  2007-02       Impact factor: 5.284

3.  Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.

Authors:  Jaimo Ahn; Lourdes Serrano de la Pena; Eileen M Shore; Frederick S Kaplan
Journal:  J Bone Joint Surg Am       Date:  2003-04       Impact factor: 5.284

4.  Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva.

Authors:  W G Kussmaul; A N Esmail; Y Sagar; J Ross; S Gregory; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1998-01       Impact factor: 4.176

5.  Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.

Authors:  Paul B Yu; Hideyuki Beppu; Noriko Kawai; En Li; Kenneth D Bloch
Journal:  J Biol Chem       Date:  2005-05-09       Impact factor: 5.157

6.  Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Micheala A Aldred; Victoria James; Rachel E Harrison; Bhakti Patel; Edward C Schwalbe; Ekkehard Gruenig; Bart Janssen; Rolf Koehler; Werner Seeger; Oliver Eickelberg; Horst Olschewski; C Gregory Elliott; Eric Glissmeyer; John Carlquist; Miryoung Kim; Adam Torbicki; Anna Fijalkowska; Grzegorz Szewczyk; Jasmine Parma; Marc J Abramowicz; Nazzareno Galie; Hiroko Morisaki; Shingo Kyotani; Norifumi Nakanishi; Takayuki Morisaki; Marc Humbert; Gerald Simonneau; Olivier Sitbon; Florent Soubrier; Florence Coulet; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mutat       Date:  2006-02       Impact factor: 4.878

7.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

8.  Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva.

Authors:  D M Rocke; M Zasloff; J Peeper; R B Cohen; F S Kaplan
Journal:  Clin Orthop Relat Res       Date:  1994-04       Impact factor: 4.176

9.  Spinal deformity in patients who have fibrodysplasia ossificans progressiva.

Authors:  P B Shah; M A Zasloff; D Drummond; F S Kaplan
Journal:  J Bone Joint Surg Am       Date:  1994-10       Impact factor: 5.284

Review 10.  Fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Martine Le Merrer; David L Glaser; Robert J Pignolo; Robert E Goldsby; Joseph A Kitterman; Jay Groppe; Eileen M Shore
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

View more
  63 in total

1.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

2.  Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Authors:  Nathalie Bravenboer; Dimitra Micha; James T Triffit; Alex N Bullock; Roberto Ravazollo; Renata Bocciardi; Maja di Rocco; J Coen Netelenbos; Peter Ten Dijke; Gonzalo Sánchez-Duffhues; Fred S Kaplan; Eileen M Shore; Robert J Pignolo; Petra Seemann; Francesc Ventura; Genevieve Beaujat; Elizabeth M W Eekhoff; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2015-01-21       Impact factor: 4.246

3.  Fibrodysplasia ossificans progressiva: a case report.

Authors:  Richard O Baidoo; Makafui S Dayie
Journal:  Ghana Med J       Date:  2016-12

4.  Primum non nocere: a case of a humeral fracture in a patient with fibrodysplasia progressiva ossificans.

Authors:  Alun Yewlett; Jeff Kitson; Andrew Redfern; Chris Smith
Journal:  Shoulder Elbow       Date:  2015-08-10

5.  The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.

Authors:  Wei Zhang; Keqin Zhang; Lige Song; Jing Pang; Hongxing Ma; Eileen M Shore; Frederick S Kaplan; Peijun Wang
Journal:  Bone       Date:  2013-09-17       Impact factor: 4.398

6.  Nanogel-Mediated RNAi Against Runx2 and Osx Inhibits Osteogenic Differentiation in Constitutively Active BMPR1A Osteoblasts.

Authors:  Arun R Shrivats; Michael C McDermott; Molly Klimak; Saadyah E Averick; Haichun Pan; Krzysztof Matyjaszewski; Yuji Mishina; Jeffrey O Hollinger
Journal:  ACS Biomater Sci Eng       Date:  2015-09-25

7.  FOP: still turning into stone.

Authors:  Reza Taslimi; Saba Jafarpour; Nahid Hassanpour
Journal:  Clin Rheumatol       Date:  2013-11-20       Impact factor: 2.980

Review 8.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

9.  General anesthesia in fibrodysplasia ossificans progressive: a case report and clinical review.

Authors:  Jin-Xing Liu; Rong Hu; Yu Sun; Hong Jiang
Journal:  Int J Clin Exp Med       Date:  2014-05-15

10.  General anesthesia for dental procedures in patients with fibrodysplasia ossificans progressiva: a review of 42 cases in 30 patients.

Authors:  Elaine Kilmartin; Zvi Grunwald; Frederick S Kaplan; Burton L Nussbaum
Journal:  Anesth Analg       Date:  2014-02       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.